Streetbeat News

Products Services

ARMP

Armata Pharmaceuticals has initiated the Phase 2A portion of its diSArm study by dosing the first patient with AP-SA02, a treatment for Staphylococcus Aureus Bacteremia.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:13 pm

MAT

Mattel, Inc. (NASDAQ:MAT) has announced a new version of Pictionary, Pictionary Vs. AI, which integrates AI technology into its gameplay. The AI guesses the players' drawings and players earn points by predicting whether the AI will guess other players' sketches correctly. The game will be available for pre-order on September 27 and will hit retail shelves on October 2. The game uses Google's Quick, Draw! artificial intelligence and has been certified by ESRB and follows COPPA compliance.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:12 pm

AAPL

Apple Inc.'s latest flagship, the iPhone 15 Pro, has a back glass that is more fragile than its predecessor. Although the replacement cost is cheaper, the fragility of the glass may lead to more frequent replacements. This issue adds to the list of controversies surrounding the iPhone 15 Pro, including discoloration, color chipping, overheating, and durability concerns.

Portfolio Pulse from Rounak Jain

September 26, 2023 | 12:11 pm

EWTX

Edgewise Therapeutics has begun enrollment for its global pivotal study, GRAND CANYON, of Edg-5506 in individuals with Becker Muscular Dystrophy. This study is an expansion of the CANYON study, which was over-enrolled with 39 adults and 24 adolescents.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:10 pm

GENI

Genius Sports (NYSE:GENI) has launched BetVision, an immersive sports betting experience that integrates live streams with bet slips, statistical insights, and real-time augmentations. The platform will allow sportsbook customers to place bets within the live video player for the first time. Caesars Sportsbook and Fanatics Sportsbook are the first to launch the product for the 2023 NFL season in the U.S. Genius Sports is the exclusive distributor of NFL Official League Data and live game video streams to sportsbooks.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:10 pm

SRFM

TXT

Surf Air Mobility (SRFM) has confirmed its exclusive relationship with Textron Aviation, a Textron Inc. (TXT) company, and announced an initial fleet order of 100 Cessna Grand Caravan EX aircraft, with an option for 50 more. Deliveries of the first 20 aircraft are expected to begin in the first half of 2024. The aircraft will be upgraded to Surf Air Mobility's proprietary electric or hybrid-electric powertrain technology. Surf Air Mobility aims to make electrified aircraft broadly available and bring the benefits of lower cost, lower emission air travel at scale to customers.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:09 pm

BFRG

Bullfrog AI has announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of Mebendazole for Glioblastoma. The study found that animals treated with BF-223 had an average survival time of 27.9 days, compared to 27.3 days for those treated with BF-222 and 23.4 days for those given a placebo.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:08 pm

SENS

Senseonics Holdings, Inc. (NYSE:SENS) has announced the completion of the ENHANCE Pivotal Clinical Study for its 365-day Continuous Glucose Monitoring System. The study is designed to evaluate the accuracy and safety of the Eversense system for one year. The data gathered will be used to support the FDA submission for the system. The company aims to secure approval for the planned 365-day Eversense system in the coming quarters.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:08 pm

GALT

Galectin Therapeutics, Inc. (NASDAQ:GALT) will present an update on its belapectin liver cirrhosis program at the 20th edition of the Discovery on Target meeting. The presentation will focus on the role of activated macrophages in liver cirrhosis and the potential of belapectin, a galectin-3 inhibitor, in treating the disease. Belapectin is currently in a Phase 2b/3 trial for the prevention of esophageal varices in NASH cirrhosis.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:08 pm

ZIMV

ZimVie has announced that it has received FDA approval to launch a study on Mobi-C Hybrid, a new product in its portfolio.

Portfolio Pulse from Bill Haddad

September 26, 2023 | 12:07 pm